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Background: CF sinonasal and bronchial mucosa reveal identical ion channel defects. Nasal Lavage (NL) allows non-invasive repeated sampling
of airway surface liquid. We compared inﬂammatory mediators in NL from CF-patients and healthy controls, and in CF in relation to sinonasal
pathogen colonization.
Methods: From 40 CF-patients (mean age 21.8 yrs, SD 11.8 yrs.) and 52 healthy controls (mean age 31.9 yrs., SD 13.7 yrs.) NL-ﬂuid (10 ml/nostril)
concentrations of MPO, IL-8, IL-17A, sICAM-1, IL-1β, IL-6, TNF-α, IL-10 and IL-5 were determined using cytometric bead arrays for ﬂow
cytometry.
Results: CF-patients showed signiﬁcantly higher MPO-concentrations in NL-ﬂuid and higher IL-8-levels (n.s.) than controls. MPO, IL-8, IL-17A,
sICAM-1, IL-1β and IL-6 were signiﬁcantly more often detectable in CF-patients than in controls. CF-patients with S. aureus colonization in both
upper and lower airways had signiﬁcantly elevated MPO and IL-8 levels in NL-ﬂuid compared to S. aureus negatives.
Conclusion: NL-ﬂuid differed substantially between CF-patients and healthy controls with most promising results for IL-8 and MPO, a primarily
in CF-NL assessed mediator. Further studies are required to assess effects of sample collection and processing on concentrations of inﬂammatory
markers and to evaluate potentials of NL analysis in research and clinical routine.
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Cystic fibrosis (CF) is characterized by viscous secretions
from exocrine glands. The resulting impaired mucociliary
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,lishedsinuses. Thus, chronic rhinosinusitis and nasal polyposis (NP) are
characteristics of CF [2], with abnormal CT sinonasal scans in
almost all patients [3]. The resulting symptoms like chronic nasal
blockage, runny nose, postnasal discharge, mouth breathing, facial
pain, anosmia, and sleep disorder considerably impair quality of
life [4,5]. Most important, chronic rhinosinusitis with impaired
mucociliary clearance converts the sinonasal space into a niche for
primary pathogen colonization. Adaptation and evolution of
pathogens at this site may be followed by their descent into the
lower airways (LAW) causing chronic pulmonary infection [6,7].
Genetic identity of pathogen pairs isolated from the UAW and
LAW of individuals with CF resulted in 96% for P. aeruginosa
and 84% for S. aureus, as we published recently [7]. However,by Elsevier B.V. All rights reserved.
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gateway and a reservoir for microbial pathogens, which in the end
is prominent for the overall survival in CF [6–11]. Common
colonization with pathogens in both airway levels underlines the
need to treat UAW and LAW as one-airway-system. In this regard
early detection of pathogens in the UAWmay facilitate eradication
before descent into the LAW and a following purposeful therapy
should further improve prognosis of CF [7].
Independent on symptomatic or causal therapy, methods to
assess inflammatory status of the airways are imperative, also for
efficacy monitoring of therapeutic measures [12]. Current
standards of airway sampling in CF include throat swabs,
(induced) sputum and bronchoalveolar lavage (BAL), the golden
standard to sample airway surface liquid but limited for its
invasiveness [13]. Although Nasal Lavage (NL) has the potential
of non-invasive and repeated sampling of the airway surface
liquid, only few authors discussed NL as diagnostic method to
evaluate CF airway inflammation [7,14–16]. In this regard, Pitrez
et al., who analyzed both airway segments by nasal wash (NW),
performed during anesthesia in supine position with 1 ml saline
using a suction catheter, and BAL from CF children, found a
significant association between IL-8 levels and the percentage of
neutrophils in both NW and BAL as well as a significant
correlation of IL-8 levels in NW and BAL. Authors concluded
that nasal inflammation may reflect lung inflammation, so that
NL could give insights into LAW pathology [14].
The aim of the present study was to assess the profiles of
selected inflammatory mediators in NL from CF patients
compared to healthy controls and to identify promising
inflammation biomarkers for further studies in this field. In
CF patients, possible differences of inflammatory patterns in
regard to sinonasal pathogen colonization should be assessed.
We analyzed the inflammation markers interleukin (IL)-8,
IL-17A, IL-10, IL-5, IL-1β, IL-6 and tumor necrosis factor
(TNF)-α as well as myeloperoxidase (MPO) and soluble
intercellular adhesion molecule (sICAM)-1.
Additionally, clinical and serological parameters including
age, criteria for chronic rhinosinusitis, allergic sensitization,
Shwachman-Score, BMI percentile, preceding sinonasal sur-
gery, current Azithromycin or nasal steroid therapy, coloniza-
tion of UAW and LAW, FEV1, MEF 75/25, IgE and IgG were
correlated to sinonasal inflammatory markers.
2. Patients, materials and methods
2.1. Study population (also see Table 2)
NL was obtained from 40 CF patients between November
2005 and February 2007. The same patients have been previously
included in a cross sectional study on sinonasal involvement in CF
[7]. Samples from a control group consisting of 52 healthy
subjects were collected prospectively. The patient group was
compared with the control group in respect of inflammation
markers in NL and assessed for correlation of biomarkers with
clinical and serological parameters which might affect inflamma-
tion such as sinonasal bacterial colonization within CF patients.
The inclusion criterion for the control group was minimal age offive years, which appears necessary for correctly performing NL.
Inclusion criteria for patients were an established diagnosis of CF
confirmed by at least two positive sweat tests and/or two
disease-causing CFTR mutations. Exclusion criteria were acute
infection, systemic antimicrobial therapy against P. aeruginosa,
sinonasal surgery within the last six months prior to recruitment of
samples, frequent nose bleeding, and perforation of the tympa-
num. Treatment with inhalative aminoglycosides or Colistin and
oral macrolides, which are common long-term therapies in CF
patients with chronic P. aeruginosa colonization, was quoted
without being exclusion criteria. Chronic P. aeruginosa coloniza-
tion was defined according to Lee et al. [17] Other diseases of the
nose, paranasal sinuses, UAW or LAW including allergic rhinitis
or other allergy associated disorders and ABPA (allergic
bronchopulmonary aspergillosis) as well as applied medications
including nasal use of topical steroids and NSAR (non-steroidal
anti-rheumatics) at the day of presentation and during the
preceding year were quoted [7]. BMI percentiles were calculated
using a web based databank (Labor Limbach, Heidelberg,
Germany).
The study was approved by the Ethics Committee of the
Faculty of Medicine, University Jena, Germany. A written
declaration of consent from all probands was obtained.
2.2. Nasal lavage
The procedures of therapeutic and diagnostic NL are similar;
they differ in applied volumes and retention time. Diagnostic NL
was performed by slowly instilling 10 ml sterile isotonic saline
into each nostril by using a 10 ml syringe, while the subject
reclined the head and closed the soft palate. The solution was
retained for approximately 10 s in the nasal cavities without
swallowing. After that, it was expulsed by forward flexing the
head, lightly exhaling and rinsing lavage liquid into a sterile
plastic beaker. Patients were strictly instructed to collect only
secretions from the nose in the sterile beaker, whereas secretions
deriving from the mouth had to be spit into the lavatory [7,18].
Immediately after collection, uncentrifuged NL-fluid was taken
up in sterile syringes and stored at 4 °C. Within 2 h after
collection, NL-fluid was aliquoted and frozen at −70 °C. Protein
concentration was measured by using a microvolume spectropho-
tometer at 280 nm wavelength (NanoDrop 1000 spectrophotom-
eter; Thermo Scientific). No anti-proteases were added.
2.3. FlowCytomix and flow cytometry
Concentration of the inflammation markers IL-1β, IL-5, IL-6,
IL-8, IL-10, IL-17A, TNF-α, the neutrophil derived enzyme
MPO, and sICAM-1 in the NL-fluid were measured by applying
a FlowCytomix (eBioscience) according to the manufacturer's
instructions. In brief, all different bead populations coated with
antibodies against the above-mentioned inflammation markers
were mixed and incubated with 25 μL NL. For detection a
biotin–streptavidin system was applied and samples were
measured by flow cytometry (FACS Calibur; BD). Results were
calculated by using the kit implemented software FlowCytomix
(eBioscience).
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For statistical analyses IBM SPSS statistics Version 19 was
used. At first, the number of samples with values above the
detection limit was counted for each analyte. Concentrations of
IL-8 and MPO were mostly above the detection limit and
subsequently analyzed by applying Mann–Whitney-U-test and
Fisher's Exact Test. For statistical evaluation of the concentra-
tions of the other factors which were mostly below the detection
limits (IL-1β, IL-5, IL-6, IL-10, IL-17A, TNF-α, and sICAM-1)
exclusively Fisher's Exact Test has been performed. (Table 3) In
order to assess possible correlations between the analyzed
inflammation markers and clinical as well as serological
parameters, the values for MPO and IL-8 were applied in a
metric scale and those for IL-1β, IL-5, IL-6, IL-10, IL-17A,
TNF-α and sICAM-1 in a nominal scale, with two values: “below
detection limit” and “above detection limit” (Table 2). For
analyzing correlations between MPO or IL-8 concentrations and
the metric or ordinal clinical variables Spearman's Rho was
applied. Differences between subgroups classified by nominal
variables were evaluated by Mann–Whitney-U-Test. Differences
in distribution of the nominally scaled analytes and the nominal
clinical variables were calculated by applying the Fisher's Exact
Test. (Table 1) All reported p-values are two-tailed and we
defined statistical significance at the 5% level.
3. Results
3.1. Demographic data
The mean age was 21.8 years (median=20.0; SD=11.8;
range: 5-65) in the 40 CF patients (19f/21 m) and 31.9 years
(median=30.0; SD=13.7; range: 9-60) in the 52 healthy
controls (38f/14 m). Allergic sensitization was found in 25/39
(64.1%) of CF patients and 17/52 (32.7%) of controls. Of these
39 CF patients with assessment of allergy, 10 (25.6%) reported
allergic rhinitis, and 12/52 (23.1%) of controls. 2 of 40 CF
patients (5.0%) suffered from ABPA. Of our 40 CF patients 2
were treated with nasal topical steroids at inclusion and none
with NSAR. Further characteristics of CF patients are presented
in Table 2.
3.2. Methodological issues
3.2.1. NL recovery
Total volumes of the retrieved NL-fluid after diagnostic
lavage with 20 ml of isotonic saline varied from 7 to 19 ml in CF
patients (n=39), and from 6 to 18 ml in controls (mean=14.2,Table 1
Statistical tests for relations between analytes and clinical and serological characteri
Analyte
Metric
MPO, I
Clinical and serological characteristics Metric/ordinal Spearm
Nominal Mann–Wrespectively 14.3 ml; median=14.0, respectively 15.0 ml; SD=
3.2, respectively 2.6 ml). Altogether, mean recovery rates
resulted in 71% respectively 72% of applied volumes.
3.2.2. Standardization of NL analyte concentrations by
concentration of total protein
As an additional parameter, which could provide information
about dilution, we measured the total protein concentration of
each NL sample. For the entity of all subjects, CF patients,
respectively controls the mean concentrations±standard error of
total protein resulted in 0.27±0.025, 0.26±0.038, respectively
0.28±0.032 mg/ml (medians: 0.22, 0.19, respectively 0.22 mg/
ml). We standardized each analyte concentration by the content
of total protein (standardized analyte concentration=analyte
concentration / concentration of total protein). Statistical analysis
of these standardized values did not yield results notably different
from those displayed in the previous paragraphs (without
standardization). In consequence, standardization to total protein
does not appear to be necessary for overcoming dilution effects in
NL.
3.3. Inflammation markers in NL
Concentrations of MPO, IL-8, IL-17A, sICAM-1, IL-1β,
IL-6, TNF-α, IL-10, and IL-5 in NL-fluid from CF patients and
healthy controls, measured by using FlowCytomix and flow
cytometry, are shown in Table 3.
The inflammation markers MPO, IL-8, IL-17A, sICAM-1,
IL-1β, and IL-6 were significantly more often detectable in NL
from CF patients than from controls (Fisher's Exact Test). Also
IL-5 was more, but TNF-α and IL-10 less frequently detectable
in CF patients than in controls (n.s.). Concentrations of MPO
and IL-8 were higher in NL-fluid from CF patients than from
controls (significant for MPO, Mann–Whitney-U-Test; Fig. 1).
Detailed results including p-values for the corresponding tests
are presented in Table 3.
3.3.1. MPO
Results are shown in Table 3 and Fig. 1a.
3.3.2. IL-8
Results are shown in Table 3 and Fig. 1b.
3.3.3. Correlation between MPO and IL-8, clinical parameters
and pathogen colonization
The statistical analysis yielded a highly significant correlation
between MPO and IL-8 concentrations (entity of all subjects: r=stics.
s
Nominal
L-8 IL-1β, IL-5, IL-6, IL-10, IL-17A, TNF-α, sICAM-1
an's Rho Mann–Whitney-U-test
hitney-U-test Chi-square test
Table 2
Clinical and serological parameters of CF patients.
Metric and ordinal variables n Mean Median SD Range
FEV1 (l) 40 2.31 1.95 1.29 0.7–4.8
FEV1 (% predicted) 40 75.46 80.00 31.34 17–132
MEF75/25 (l/s) 40 2.17 1.55 2.03 0.4–10.8
MEF75/25 (% predicted) 40 57.36 58.00 40.00 7–163
Shwachman-Score (without Chest-X-Ray) 40 64.38 70.00 15.33 30–75
BMI percentile 40 24.75 24.20 19.61 0–69.1
Nominal variables n Absolute frequency (%)
Preceding sinonasal surgery 40 19 (47.5)
Current Azithromycin therapy 40 19 (47.5)
Current nasal steroid therapy 40 3 (7.5)
IgE elevated 38 15 (39.5)
IgG elevated 34 11 (32.4)
No Acute Remittent Chronic
EPOS-criteria for chronic rhinosinusitis a 0 (0.0) 31 (86.1) 5 (13.9)
Nasal blockage or obstruction or congestion 0 (0.0) 30 (83.3) 6 (16.7)
Anterior or posterior nasal drip 0 (0.0) 27 (75.0) 9 (25.0)
Facial pain or pressure 20 (55.6) 15 (41.7) 1 (2.8)
Reduction or loss of smell 17 (47.2) 12 (33.3) 7 (19.4)
Permanent colonization LAW: 40
P. aeruginosa (non-mucoid P.a./mucoid P.a.) 3/15 (37.5/7.5)
S. aureus (MSSA/MRSA) 19/1 (2.5/47.5)
Detection in UAW: 40
P. aeruginosa (non-mucoid P.a./mucoid P.a.) 4 / 9 (22.5 / 10.0)
S. aureus (MSSA/MRSA) 15/1 (2.5/37.5)
detection in LAW: 40
P. aeruginosa (non-mucoid P.a./mucoid P.a.) 5/12 (30.0/12.5)
S. aureus (MSSA/MRSA) 15/1 (2.5/37.5)
Abbreviations: SD = standard deviation; FEV1 = forced expiratory volume in one second; MEF75/25 = maximal expiratory flow between 25 and 75% of forced vital
capacity; BMI = bodymass index; IgE = immunoglobulin E; IgG = immunoglobulin G; LAW= lower airways; UAW= upper airways;P. aeruginosa = P.a. = Pseudomonas
aeruginosa; S. aureus = Staphylococcus aureus; MRSA = Methicillin-resistant Staphylococcus aureus; MSSA = Methicillin-sensitive Staphylococcus aureus.
a Clinical deﬁnition criteria of rhinosinusitis with 3 groups “no symptoms” (no), “acute/ intermittent symptoms (b12 weeks/year)” (acute) and “chronic symptoms
(≥12 weeks/year)” (chronic) according to the 2007 EPOS consensus paper (European Position Paper on Rhinosinusitis and Nasal Polyps from the European
Academy of Allergology and Clinical Immunology) [20].
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0.570, pb0.001).
Furthermore, we found a significant negative correlation
between IL-8 concentration and age in the entity of all subjects
(r= -0.245; p=0.018), and between MPO concentration and
recovered fluid volume in controls (r= -0.462; p=0.001) but
not in CF patients. MPO and IL-8 did not significantly correlate
with other metric and ordinal variables (Table 2).
MPO concentration was significantly elevated in males
(p=0.034) and in allergic subjects (p=0.043) in the entity of
all subjects. We also found an increased MPO concentration
in CF patients with previous sinonasal surgery (p=0.003).
Following, we focused on UAW colonization and separated
CF patients in four groups: both S. aureus and P. aeruginosa
(UAW-SA+PA; n=3), exclusively S. aureus (UAW-SA; n=13),
exclusively P. aeruginosa (UAW-PA; n=10) and no colonization
of UAW (UAW-0; n=14). MPO and IL-8 levels in NL-fluid were
significantly higher in UAW-SA compared to UAW-0 (p=0.002,
each) and UAW-PA (MPO: p=0.013; IL-8: p=0.015). Neither
other comparison between subgroups yielded statistically signif-
icant concentration differences (Fig. 2).There were no significant differences between the groups
regarding the other nominal variables (Table 2) with respect to
MPO respectively IL-8 concentrations.
3.3.4. IL-17A, sICAM-1, IL-1β, IL-6, TNF-α, IL-10, and IL-5
IL-17A, sICAM-1, IL-1β and IL-6 were detected signifi-
cantly more frequent above the detection limit in NL-fluid from
CF patients than from healthy controls. It is noticeable that in
the control group the concentration of sICAM-1 was not found
above the detection limit in any sample and there was only one
sample with IL-6 concentration situated above the detection
limit.
In CF patients TNF-α and IL-10 were found more often
below the detection limit than in controls, but this difference
did not reach statistical significance. For IL-5 we found similar
frequencies of detection for CF patients and controls (n.s.).
4. Discussion
CF sinonasal mucosa reveals the same ion channel defect as
LAW mucosa, resulting in defective mucociliary clearance at
Table 3
Inflammation markers in NL from CF patients and healthy controls (sorted by frequency of detection).
Analyte (Unit) DL Frequency of detection
(%)
Median Range (Min–Max) p
CF Controls CF Controls CF Controls CF:controls
MPO
(ng/ml)
0.02 100.0 71.2 110.8 33.4 16.5–731.3 0.0–182.7 b0.001 a
b0.001 b
IL-8
(pg/ml)
0.5 85.0 61.5 47.5 92.6 0.0–11514.8 0.0–3492.5 0.019 a
n.s. b
IL-17A
(pg/ml)
2.5 35.0 5.8 0.0 0.0 0.0–47.5 0.0–123.3 0.001 a
sICAM-1
(ng/ml)
5.3 17.5 0.0 0.0 0.0 0.0–33.2 (0 VNDL) 0.002 a
IL-1β
(pg/ml)
4.2 17.5 3.8 0.0 0.0 0.0–152.8 0.0–394.9 0.038 a
IL-6
(pg/ml)
1.2 15.0 1.9 0.0 0.0 0.0–80.2 0.0–90.9 0.040 a
TNF-α
(pg/ml)
3.2 10.0 15.4 0.0 0.0 0.0–46.6 0.0–93.1 n.s. a
IL-10
(pg/ml)
1.9 10.0 15.4 0.0 0.0 0.0–42.5 0.0–84.7 n.s. a
IL-5
(pg/ml)
1.6 10.0 7.7 0.0 0.0 0.0–57.2 0.0–182.6 n.s. a
Abbreviations: NL = nasal lavage; DL = detection limit; SD = standard deviation; Min = Minimum; Max = Maximum; VNDL = value/s above the detection limit;
MPO = myeloperoxidase; IL = interleukin; sICAM-1 = soluble intercellular adhesion molecule 1; TNF- α = tumor necrosis factor α.
a Fisher's Exact Test for comparison of frequency of positive samples (5% signiﬁcance level, two-tailed).
b Mann–Whitney-U-Test for comparison of measured concentrations (5% signiﬁcance level, two-tailed).
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inflammatory patterns in CF have not been sufficiently assessed.
The present preliminary study was performed to assess
potential soluble inflammation markers in NL from CF patients
for following studies in this field and to compare results to
findings from healthy controls.
Altogether, concentrations of MPO, IL-8, IL-17A, sICAM-1,
IL-1β, and IL-6 exceeded the detection limit significantly more
often in CF patients than in controls, whereas there were no
significant differences in TNF-α, IL-10, and IL-5 concentrations
between both groups.
4.1. Limitations
The present manuscript compares mediator concentrations in
NL fluid from a well-defined CF cohort sampled 5 years beforea
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Fig. 1. Comparison of MPO (a) and IL-8 (b) concentration between CF patients and
patients (4299.1; 4469.3; 11514.8 pg/ml) in (b) are not shown because of scaling.analysis and frozen at −70 °C within 2 h after sampling with NL
fluid from healthy controls obtained 2 months before analysis
and equally frozen at −70 °C within comparable times.
Differences in storing times can have effects on mediator
concentrations. For one of the principle parameters, IL-8, this
question has been assessed previously by Berry et al. finding
that storage at temperatures as applied to our samples did not
influence IL-8 concentrations for up to 6 years [19]. Additionally,
for most mediators assessed within our trial population the longer
stored samples resulted significantly higher and/or significantly
more often positive for the mediators than samples from our
healthy controls.
Additionally, mean age of controls differed from mean age of
CF patients. However, mediator concentrations in NL between
patients and controls were so marked, that we do not expect
relevant bias from age differences between the groups.CF
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Fig. 2. Comparison of MPO (a) resp. IL-8 concentration (b) in respect of UAW colonization, four subgroups: both S. aureus and P. aeruginosa (UAW-SA+PA; n=3),
exclusively S. aureus (UAW-SA; n=13), exclusively P. aeruginosa (UAW-PA; n=10) and no colonization (UAW-0; n=14). p-values for statistically significant
differences between groups are represented. Extreme values of UAW-SA (11514.8; 4469.3; 4299.1 pg/ml) in (b) are not shown because of scaling.
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Compared to healthy controls CF patients had significantly
higher MPO concentrations in NL-fluid. This finding is new, as to
our knowledge, MPO has not been assessed previously in NL
from CF patients. MPO is a neutrophil-derived protein released
during oxidative burst and catalyzes the production of various
oxidants, so that elevated levels can be regarded as markers for
neutrophil activity [20,21]. Previously, in CF elevated MPO
concentrations were found in serum [22], sputum [23–25], and
BAL compared to healthy controls [21,26]. Also, surgically
obtained sinonasal mucosal tissue from CF patients with NP had
significantly higher MPO concentrations compared to healthy
controls (pb0.001) [27,28]. Peroxidase activity and MPO
concentration in BAL-fluid were significantly higher in CF
patients than in healthy controls and both parameters correlated
strongly in CF (r2=0.84, pb0.001). The authors stated that MPO
is the predominant peroxidase in BAL-fluid from childrenwith CF
[21]. Downey and coworkers showed that MPO in CF sputum has
relevant correlation with the course of the patients' disease as it
was significantly increased in participants who did not survive the
study period. Therefore, elevated MPO levels in CF airways seem
to be linked to a poorer outcome [29] and it is a most promising
marker for further studies in this field.
4.3. IL-8
Compared to healthy controls IL-8 was more often detectable
in CF patients. The chemotactic active cytokine IL-8 attracts
neutrophils to migrate from the circulatory system into surround-
ing tissue and activates neutrophil degranulation [15]. Previous
studies revealed significantly increased IL-8 concentrations in
NL-fluid from CF patients compared to healthy controls
(pb0.001, respectively pb0.0001) [15,30] and patients with
idiopathic NP (pb0.05) without revealing differences between
CF patients with and without NP [15]. In accordance to these
studies, we found IL-8 concentrations in NL-fluid significantly
more often above the detection limit in CF patients than in
controls. However, in our cohort concentration differencesbetween CF patients and controls did not reach statistical
significance because of relatively high variance of values.
Thereby, we exclude storage effects on IL-8 levels, which
were proven stable in BAL-fluid for up to 6 years at −80 °C
[19], as stored in our CF cohort. IL-8 concentrations might
increase with age of subjects, as reported for induced sputum
for both CF patients and non-CF controls (r =0.41; pb0.05)
[31]. Therefore, this might act as a minor confounder in our
study with higher mean age in controls.
Additionally, in NL-fluid from children with CF Noah et al.
found slightly lower median IL-8 concentrations than in controls
(186 pg/ml vs. 204 pg/ml; n.s.) [32] as McShane et al. who even
reported undetectable IL-8 concentrations in the majority of NL
samples from adult CF patients [33]. Differences may be due to
different assessment methods and detection limits. Further
studies are necessary in order to identify confounding factors
and to standardize the method of analyzing NL.
4.4. Correlation between MPO and IL-8 as well as pathogen
colonization
In the present study MPO and IL-8 concentrations in
NL-fluid correlated with high significance for all assessed
groups. This accords to our expectations, as both IL-8 and
MPO are markers of neutrophil activity [15,20].
Focusing on UAW pathogen colonization it is remarkable
that both inflammation markers were significantly elevated in
CF patients with solitary S. aureus colonization compared to
those with solitary P. aeruginosa colonization or pathogen
negatives (Fig. 2). These findings in NL accord to Sagel et al.,
who found significantly higher IL-8 concentrations in BAL-
fluid from CF patients with detection of S. aureus compared to
those without S. aureus detection [34]. Apparently, S. aureus
gives a strong stimulus for UAW inflammation, even more
pronounced than P. aeruginosa. In this regard, enterotoxins
released from S. aureus are discussed to act as superantigens on
inflammatory T- and B-cells as well as eosinophils. Via type 2
helper T-cells this stimulus is reported to lead to an eosinophilic
inflammation and IgE production which exacerbates disease in the
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inflammatory stimulus of S. aureus can be ascertained with larger
collectives.
4.5. IL-17A, sICAM-1, IL-1β, IL-6, TNF-α, IL-10, and IL-5
We detected IL-17A in NL-fluid significantly more frequent
in CF patients. IL-17A is a pro-inflammatory cytokine produced
by activated memory T-cells and stimulates granulopoiesis
through regulating the expression of G-CSF (granulocyte
colony-stimulating factor) as well as the mobilization of
neutrophils via a signaling pathway including lung fibroblasts
and airway epithelial cells which induce a gradient of chemokines
[36,37]. In the available publications IL-17A was not assessed in
CF UAW material and this cytokine is promising for future
studies applyingmethods with lower detection limits (e.g. ELISA
techniques).
sICAM-1 could be detected in 17.5% of NL samples from
CF patients but not in controls (highly significant difference).
Also sICAM-1 has not been assessed in present publications on
CF UAW and it appears promising for methods with higher
sensitivity.
Also the significantly more frequent detection of the pro-
inflammatory cytokine IL-1β [38], which has not been assessed
previously in NL from CF patients, correlates to previous
publications. Significantly higher IL-1β levels were found in
sinonasal mucosal tissue from CF patients with NP compared to
controls, to patients with chronic rhinosinusitis and to non-CF
patients with NP [27]. The mediator also was elevated in CF
LAW samples [39–43].
In NL-fluid we also detected the pro-inflammatory
cytokine IL-6 [38] significantly more often in CF patients
than in controls. A previous paper reported IL-6 detection
frequency of 19% in NL from healthy subjects [20]. In another
study, mean IL-6 concentrations in NL-fluid from adult
healthy volunteers were approximately 5 pg/ml [44]. Both
research groups used ELISA for measuring IL-6 [20,44],
which had a lower detection limit than the bead arrays used in
our study.
The pro-inflammatory cytokine TNF-α [38] seems to be
unsuitable as inflammation marker in NL, with the current
detection methods was found in 10% of CF patients and 15% of
controls. In the only available study assessing TNF-α in NL
from CF patients, TNF-α was reported as undetectable by the
applied ELISA [33].
The detection frequencies of the anti-inflammatory cyto-
kine IL-10 [12], and IL-5, which plays a decisive role in
recruitment and activation of eosinophils [45], were not
significantly different between NL-fluid from CF patients and
controls. Alone Noah et al. investigated the IL-10 concentra-
tion in NL-fluid from CF patients compared to healthy
controls before us without finding significant differences but
speculating about a trend towards lower IL-10 levels in
NL-fluid from CF patients [32]. The small number of
detectable IL-5 concentrations in NL-fluid was also noted
from Henriksson et al., who did not find measurable levels in
CF NL-fluid [30].4.6. Method of diagnostic NL
Current standard methods to sample airways include throat
swabs, (induced) sputum, and BAL [13]. NL, which does not
belong to present routine CF management, allows simultaneous
assessment of inflammation and pathogen colonization like the
other mentioned techniques. Its strong advantage over BAL is
non-invasiveness within sampling of airway surface liquid. Its
potential side effect is aspiration of isotonic saline at lower
levels than by swimming in the sea. For other diseases like
bronchial asthma NL as a diagnostic tool to sample airway
surface liquid has been assessed previously with promising
results for IL-6, IL-8, and ECP (eosinophil cationic protein) and
undetectable mediators like GM-CSF (granulocyte-macrophage
colony-stimulating factor) [46].
Marked differences in patterns of soluble inflammation
markers between CF patients and controls make NL highly
interesting as surrogate parameter for studies applying novel
systemic therapeutic options including chloride channel activa-
tors and potentiators [47]: effective drugs could bring inflamma-
tion patterns in airway surface liquid down, near to the level of
healthy controls. As BAL is not suitable for frequent controls,
and nasal potential measurement is far too complicated for
frequent application in multiple study sites, airway surface liquid
sampling by NL would be most promising. In this regard further
investigation of NL potentials can contribute to further improve-
ment of the course of CF [5,11].
5. Conclusions
Non-invasive methods which allow repeated sampling of
airway surface liquid within routine care are of special interest. In
this preliminary study, which compares NL from CF patients and
healthy controls, we found substantial differences of inflamma-
tion markers with some remarkable relation to specific pathogens
detected within same CF NL fluid samples. Especially MPO,
which is measured for the first time in NL-fluid from CF patients,
and IL-8 are easily quantifiable by the applied cytokine bead
arrays. Some interesting markers might require more sensitive
assays. Future studies in this promising field should focus on
methodological questions including standardization of sampling
and processing methods; they should include assessment of
cytology in regard to colonization status and compare UAW and
LAW surface liquid.
Funding statement
The study was supported by funds from Hoffmann La Roche,
Novartis, InfectoPharm, Pari, and Gruenenthal. We confirm that
the financial support did not influence any aspect of the study and
that no other financial resources were provided.
Acknowledgment
We thank Claudia Schien, Franziska Bucksch, Stefan Neubeck,
Uta Enke, Sebastian Hölters, Nele Fischer, Ralf Häfer, Thomas
Lehmann, and Toni Neuwirth for their support in the study and the
256 N. Beiersdorf et al. / Journal of Cystic Fibrosis 12 (2012) 249–257preparation of the manuscript. The authors especially thank the
patients and the healthy volunteers who participated in this study
as well as their families.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2012.08.015.
References
[1] Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med
2005;352(19):1992-2001.
[2] Mainz JG, Koitschev A. Pathogenesis and management of nasal polyposis
in cystic fibrosis. Curr Allergy Asthma Rep 2012;12(2):163-74.
[3] Eggesbø HB, Søvik S, Dølvik S, Eiklid K, Kolmannskog F. CT
characterization of developmental variations of the paranasal sinuses in
cystic fibrosis. Acta Radiol 2001;42(5):482-93.
[4] Gysin C, Alothman GA, Papsin BC. Sinonasal disease in cystic fibrosis:
clinical characteristics, diagnosis, and management. Pediatr Pulmonol
2000;30(6):481-9.
[5] Mainz JG, Koitschev A. Management of chronic rhinosinusitis in CF. J Cyst
Fibros 2009;8(Suppl. 1):S10-4.
[6] Hansen SK, Rau MH, Johansen HK, Ciofu O, Jelsbak L, Yang L, et al.
Evolution and diversification of Pseudomonas aeruginosa in the paranasal
sinuses of cystic fibrosis children have implications for chronic lung infection.
ISME J 2012;6(1):31-45, http://dx.doi.org/10.1038/ismej.2011.83. Epub 2011
Jun 30.
[7] Mainz J, Naehrlich L, Schien M, Käding M, Schiller I, Mayr S, et al.
Concordant genotype of upper and lower airways P aeruginosa and S. aureus
isolates in cystic fibrosis. Thorax 2009;64(6):535-40.
[8] Taylor RF, Morgan DW, Nicholson PS, Mackay IS, Hodson ME, Pitt TL.
Extrapulmonary sites of Pseudomonas aeruginosa in adults with cystic
fibrosis. Thorax 1992;47(6):426-8.
[9] Dosanjh A, Lakhani S, Elashoff D, Chin C, Hsu V, Hilman B. A comparison
of microbiologic flora of the sinuses and airway among cystic fibrosis
patients with maxillary antrostomies. Pediatr Transplant 2000;4(3):182-5.
[10] Muhlebach MS, Miller MB, Moore C, Wedd JP, Drake AF, Leigh MW.
Are lower airway or throat cultures predictive of sinus bacteriology in
cystic fibrosis? Pediatr Pulmonol 2006;41(5):445-51.
[11] Mainz JG, Michl R, Pfister W, Beck JF. Cystic fibrosis upper airways
primary colonization with Pseudomonas aeruginosa: eradicated by
sinonasal antibiotic inhalation. Am J Respir Crit Care Med 2011;184(9):
1089-90.
[12] Elizur A, Cannon C, Ferkol T. Airway inflammation in cystic fibrosis.
Chest 2008;133(2):489-95.
[13] Ratjen F. Diagnosing and managing infection in CF. Paediatr Respir Rev
2006;7(Suppl. 1):S151-3.
[14] Pitrez PM, Brennan S, Turner S, Sly PD. Nasal wash as an alternative to
bronchoalveolar lavage in detecting early pulmonary inflammation in
children with cystic fibrosis. Respirology 2005;10(2):177-82.
[15] Bergoin C, Gosset P, Lamblin C, Bolard F, Turck D, Tonnel A, et al. Cell
and cytokine profile in nasal secretions in cystic fibrosis. J Cyst Fibros
2002;1(3):110-5.
[16] Nikasinovic-Fournier L, Just J, Seta N, Callais F, Sahraoui F, Grimfeld A,
et al. Nasal lavage as a tool for the assessment of upper-airway inflammation
in adults and children. J Lab Clin Med 2002;139(3):173-80.
[17] Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation
of a new definition for chronic Pseudomonas aeruginosa infection in cystic
fibrosis patients. J Cyst Fibros 2003;2(1):29-34.
[18] Howarth PH, Persson CGA, Meltzer EO, Jacobson MR, Durham SR,
Silkoff PE. Objective monitoring of nasal airway inflammation in rhinitis.
J Allergy Clin Immunol 2005;115(3 Suppl. 1):S414-41.
[19] Berry LJ, Sheil B, Garratt L, Sly PD, CFA. Stability of interleukin 8 and
neutrophil elastase in bronchoalveolar lavage fluid following long-term
storage. J Cyst Fibros 2010;9(5):346-50.[20] Zhang YJ, Luroe S, Schieber F, Kelsey J, Nabbie F, Rizzi G, et al.
Immunoassay-based measurement of clinical biomarkers for monitoring
changes in nasal cavity. J Pharm Biomed Anal 2009;50(5):823-30.
[21] Thomson E, Brennan S, Senthilmohan R, Gangell CL, Chapman AL, Sly
PD, et al. Identifying peroxidases and their oxidants in the early pathology
of cystic fibrosis. Free Radic Biol Med 2010;49(9):1354-60.
[22] Koller DY, Götz M, Wojnarowski C, Eichler I. Relationship between
disease severity and inflammatory markers in cystic fibrosis. Arch Dis
Child 1996;75(6):498-501.
[23] Van Der Vliet A, Nguyen MN, Shigenaga MK, Eiserich JP, Marelich GP,
Cross CE. Myeloperoxidase and protein oxidation in cystic fibrosis. Am J
Physiol Lung Cell Mol Physiol 2000;279(3):L537-46.
[24] Koller DY, Götz M, Eichler I, Urbanek R. Eosinophilic activation in cystic
fibrosis. Thorax 1994;49(5):496-9.
[25] Jones KL, Hegab AH, Hillman BC, Simpson KL, Jinkins PA, Grisham
MB, et al. Elevation of nitrotyrosine and nitrate concentrations in cystic
fibrosis sputum. Pediatr Pulmonol 2000;30(2):79-85.
[26] Kettle AJ, Chan T, Osberg I, Senthilmohan R, Chapman AL, Mocatta TJ,
et al. Myeloperoxidase and protein oxidation in the airways of young
children with cystic fibrosis. Am J Respir Crit Care Med 2004;170(12):
1317-23.
[27] Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van
Cauwenberge P, et al. Differentiation of chronic sinus diseases bymeasurement
of inflammatory mediators. Allergy 2006;61(11):1280-9.
[28] Claeys S, Van Hoecke H, Holtappels G, Gevaert P, De Belder T,
Verhasselt B, et al. Nasal polyps in patients with and without cystic
fibrosis: a differentiation by innate markers and inflammatory mediators.
Clin Exp Allergy 2005;35(4):467-72.
[29] Downey DG, Martin SL, Dempster M, Moore JE, Keogan MT, Starcher B,
et al. The relationship of clinical and inflammatory markers to outcome in
stable patients with cystic fibrosis. Pediatr Pulmonol 2007;42(3):216-20.
[30] Henriksson G, Westrin KM, Karpati F, Wikström AC, Stierna P, Hjelte L.
Nasal polyps in cystic fibrosis: clinical endoscopic study with nasal lavage
fluid analysis. Chest 2002;121(1):40-7.
[31] Mussaffi H, Fireman EM, Mei-Zahav M, Prais D, Blau H. Induced sputum
in the very young: a new key to infection and inflammation. Chest
2008;133(1):176-82.
[32] Noah TL, Black HR, Cheng PW, Wood RE, Leigh MW. Nasal and
bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis
1997;175(3):638-47.
[33] McShane D, Davies JC, Wodehouse T, Bush A, Geddes D, Alton EW.
Normal nasal mucociliary clearance in CF children: evidence against a
CFTR-related defect. Eur Respir J 2004;24(1):95–100.
[34] Sagel SD, Gibson RL, Emerson J,McNamara S, Burns JL,Wagener JS, et al.
Impact of Pseudomonas and Staphylococcus infection on inflammation and
clinical status in young children with cystic fibrosis. J Pediatr 2009;154(2):
183-8.
[35] Bachert C, Gevaert P, Zhang N, van Zele T, Perez-Novo C. Role of
staphylococcal superantigens in airway disease. Chem Immunol Allergy
2007;93:214-36.
[36] Dubin PJ, McAllister F, Kolls JK. Is cystic fibrosis a TH17 disease?
Inflamm Res 2007;56(6):221-7.
[37] Kolls JK, Lindén A. Interleukin-17 family members and inflammation.
Immunity 2004;21(4):467-76.
[38] Fokkens W, Lund V, Mullol J, group EPPoRaNP. European position
paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl 2007;20:
1–136.
[39] Coulter KR, Allen ED, Hart J, Wewers MD, Castile RG, Knoell DL.
Induction of interleukin-8 release by lung epithelium with cystic fibrosis
epithelial lining fluid is marginally affected by inhibitors of interleukin-1beta.
Pharmacotherapy 2000;20(1):64-74.
[40] Eickmeier O, Huebner M, Herrmann E, Zissler U, Rosewich M, Baer PC,
et al. Sputum biomarker profiles in cystic fibrosis (CF) and chronic
obstructive pulmonary disease (COPD) and association between pulmo-
nary function. Cytokine 2010;50(2):152-7.
[41] Reid DW, Lam QT, Schneider H, Walters EH. Airway iron and
iron-regulatory cytokines in cystic fibrosis. Eur Respir J 2004;24(2):
286-91.
257N. Beiersdorf et al. / Journal of Cystic Fibrosis 12 (2012) 249–257[42] Osika E, Cavaillon JM, Chadelat K, Boule M, Fitting C, Tournier G, et al.
Distinct sputum cytokine profiles in cystic fibrosis and other chronic
inflammatory airway disease. Eur Respir J 1999;14(2):339-46.
[43] Schuster A, HaarmannA,WahnV. Cytokines in neutrophil-dominated airway
inflammation in patients with cystic fibrosis. Eur Arch Otorhinolaryngol
1995;252(Suppl. 1):S59-60.
[44] Bachert C, van Kempen MJ, Höpken K, Holtappels G, Wagenmann M.
Elevated levels of myeloperoxidase, pro-inflammatory cytokines and
chemokines in naturally acquired upper respiratory tract infections. Eur
Arch Otorhinolaryngol 2001;258(8):406-12.[45] Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79(12):
3101-9.
[46] Noah TL, Tudor GE, Ivins SS, Murphy PC, Peden DB, Henderson FW.
Repeated measurement of nasal lavage fluid chemokines in school-age
children with asthma. Ann Allergy Asthma Immunol 2006;96(2):304-10.
[47] Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P,
et al. A CFTR potentiator in patients with cystic fibrosis and the G551D
mutation. N Engl J Med 2011;365(18):1663-72.
